[Clinical analysis of 140 cases of mantle cell lymphoma].

Objective: To study the clinical features, therapeutic effects, prognostic factors of 140 patents with mantle cell lymphoma (MCL). Methods: Clinical data of 140 MCL patients admitted from June 2009 to January 2016 in our hospital were retrospectively analyzed. Results: The median age of 140 patients was 59 years with a ratio of 6∶1 for men and women. There were 134 cases (95.7%) in Ann-Arbor stage Ⅲ-Ⅳ, 37 cases (26.4%) with B symptoms, 61 cases (43.6%) with bone marrow involvement and 38 cases (27.1%) with enlarged spleen. The overall response rate (ORR), 3-year survival rate and progression-free survival rate in the treatment group with rituximab were 87.1%, 68.1% and 59.5% respectively, which were significantly higher than those in the rituximab-free treatment group (66.6%, 51.5% and 31.7%, respectively). The difference was statistically significant (all P <0.05). Among patients treated with rituximab, the complete remission rates (70.8% and 77.8%) of R-HyperCVAD/MA and VcR-CAP regimens were higher than those of R-CHOP regimen (39.0%, both P <0.05). However, there was no significant difference in the overall response rate, overall survival rate and progression-free survival rate (all P >0.05). Univariate analysis showed that age, Ki-67 index, B symptoms, bone marrow invasion, platelet count, LDH, β(2)-MG and MIPI scores were associated with overall survival (all P <0.05). Multivariate analysis showed that age ( HR =4.940, 95% CI: 2.347 to 10.397), B symptom ( HR =2.900, 95% CI: 1.517-5.544), β(2)-MG ( HR =2.945, 95% CI: 1.656-5.238), Ki-67 index ( HR =4.915, 95% CI: 2.554-9.456) and treatment with rituximab-containing regimen ( HR =2.450, 95% CI: 1.352-4.440) were independent factors for OS. Conclusions: Most patients with MCL were older adults and usually had bone marrow involvement and spleen involvement. Rituximab combined with chemotherapy (especially R-HyprCVAD/MA and VcR-CAP) had better clinical efficacy than conventional chemotherapy.